In vivo imaging translocator protein (TSPO) in autism spectrum disorder.
Journal
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology
ISSN: 1740-634X
Titre abrégé: Neuropsychopharmacology
Pays: England
ID NLM: 8904907
Informations de publication
Date de publication:
06 2022
06 2022
Historique:
received:
05
10
2021
accepted:
07
03
2022
revised:
01
03
2022
pubmed:
7
4
2022
medline:
21
5
2022
entrez:
6
4
2022
Statut:
ppublish
Résumé
Converging evidence points to the significant involvement of the immune system in autism spectrum disorders (ASD). Positron emission tomography (PET) can quantify translocator protein 18 kDa (TSPO), a marker with increased expression mainly in microglia and, to some extent astroglia during neuropsychiatric diseases with inflammation. This preliminary analysis explored, for the first time, whether TSPO binding was altered in male and female participants with ASD in vivo using full kinetic quantification. Thirteen individuals with ASD (IQ > 70 [n = 12], IQ = 62 [n = 1]), 5 F, 25 ± 5 years) were scanned with [
Identifiants
pubmed: 35383319
doi: 10.1038/s41386-022-01306-4
pii: 10.1038/s41386-022-01306-4
pmc: PMC9117200
doi:
Substances chimiques
Anilides
0
Pyridines
0
Receptors, GABA
0
TSPO protein, human
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1421-1427Subventions
Organisme : CIHR
ID : MOP-142376
Pays : Canada
Informations de copyright
© 2022. The Author(s), under exclusive licence to American College of Neuropsychopharmacology.
Références
American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5). Arlington, VA. American Psychiatric Association Publishing; 2013.
Park HR, Lee JM, Moon HE, Lee DS, Kim BN, Kim J, et al. A short review on the current understanding of autism spectrum disorders. Exp Neurobiol. 2016;25:1–13.
pubmed: 26924928
pmcid: 4766109
doi: 10.5607/en.2016.25.1.1
Ofner MCA, Decou ML, Do MT, Bienek A, Snider J, Ugnat AM. The prevalence of autism spectrum disorder (ASD) among 5-17 year olds in seven provinces and territories in Canada in 2015 A national ASD surveillance system (NASS) report. Ottawa, ON: Public Health Agency of Canada; 2018.
Ronald A, Hoekstra RA. Autism spectrum disorders and autistic traits: a decade of new twin studies. American journal of medical genetics Part B, Neuropsychiatric genetics: the official publication of the International Society of Psychiatric Genetics. Am J Med Genet Part B, Neuropsychiatr Genet. 2011;156B:255–74.
doi: 10.1002/ajmg.b.31159
Lord CEM, Baird G, Veenstra-Vanderweele J. Autism spectrum disorder. Lancet. 2018;392:508–20.
pubmed: 30078460
pmcid: 7398158
doi: 10.1016/S0140-6736(18)31129-2
Xu G, Strathearn L, Liu B, O'brien M, Kopelman TG, Zhu J, et al. Prevalence and treatment patterns of autism spectrum disorder in the United States, 2016. JAMA Pediatr. 2019;173:153–59.
pubmed: 30508021
doi: 10.1001/jamapediatrics.2018.4208
Kogan MD, Vladutiu CJ, Schieve LA, Ghandour RM, Blumberg SJ, Zablotsky B, et al. The prevalence of parent-reported autism spectrum disorder among US children. Pediatrics. 2018;142:e20174161
De Rubeis S, He X, Goldberg AP, Poultney CS, Samocha K, Cicek AE, et al. Synaptic, transcriptional and chromatin genes disrupted in autism. Nature. 2014;515:209–15.
pubmed: 25363760
pmcid: 4402723
doi: 10.1038/nature13772
Rudie JD, Brown JA, Beck-Pancer D, Hernandez LM, Dennis EL, Thompson PM, et al. Altered functional and structural brain network organization in autism. NeuroImage Clin. 2013;2:79–94.
doi: 10.1016/j.nicl.2012.11.006
McDougle CJ, Landino SM, Vahabzadeh A, O’Rourke J, Zurcher NR, Finger BC, et al. Toward an immune-mediated subtype of autism spectrum disorder. Brain Res. 2015;1617:72–92.
Asadabadi M, Mohammadi MR, Ghanizadeh A, Modabbernia A, Ashrafi M, Hassanzadeh E, et al. Celecoxib as adjunctive treatment to risperidone in children with autistic disorder: a randomized, double-blind, placebo-controlled trial. Psychopharmacology. 2013;225:51–59.
pubmed: 22782459
doi: 10.1007/s00213-012-2796-8
McAllister AK, Patterson PH. Introduction to special issue on neuroimmunology in brain development and disease. Dev Neurobiol. 2012;72:1269–71.
pubmed: 22927111
pmcid: 4357356
doi: 10.1002/dneu.22054
Croonenberghs J, Wauters A, Devreese K, Verkerk R, Scharpe S, Bosmans E, et al. Increased serum albumin, gamma globulin, immunoglobulin IgG, and IgG2 and IgG4 in autism. Psychol Med. 2002;32:1457–63.
pubmed: 12455944
doi: 10.1017/S0033291702006037
Rossignol DA, Frye RE. A review of research trends in physiological abnormalities in autism spectrum disorders: immune dysregulation, inflammation, oxidative stress, mitochondrial dysfunction and environmental toxicant exposures. Mol Psychiatry. 2012;17:389–401.
pubmed: 22143005
doi: 10.1038/mp.2011.165
Ashwood P, Enstrom A, Krakowiak P, Hertz-Picciotto I, Hansen RL, Croen LA, et al. Decreased transforming growth factor beta1 in autism: a potential link between immune dysregulation and impairment in clinical behavioral outcomes. J Neuroimmunol. 2008;204:149–53.
pubmed: 18762342
pmcid: 2615583
doi: 10.1016/j.jneuroim.2008.07.006
Morgan JT, Chana G, Pardo CA, Achim C, Semendeferi K, Buckwalter J, et al. Microglial activation and increased microglial density observed in the dorsolateral prefrontal cortex in autism. Biol Psychiatry. 2010;68:368–76.
pubmed: 20674603
doi: 10.1016/j.biopsych.2010.05.024
Vargas DL, Nascimbene C, Krishnan C, Zimmerman AW, Pardo CA. Neuroglial activation and neuroinflammation in the brain of patients with autism. Ann Neurol. 2005;57:67–81.
pubmed: 15546155
doi: 10.1002/ana.20315
Venneti S, Wang G, Nguyen J, Wiley CA. The positron emission tomography ligand DAA1106 binds with high affinity to activated microglia in human neurological disorders. J Neuropathol Exp Neurol. 2008;67:1001–10.
pubmed: 18800007
doi: 10.1097/NEN.0b013e318188b204
Cosenza-Nashat M, Zhao ML, Suh HS, Morgan J, Natividad R, Morgello S, et al. Expression of the translocator protein of 18 kDa by microglia, macrophages and astrocytes based on immunohistochemical localization in abnormal human brain. Neuropathol Appl Neurobiol. 2009;35:306–28.
pubmed: 19077109
doi: 10.1111/j.1365-2990.2008.01006.x
Betlazar C, Harrison-Brown M, Middleton RJ, Banati R, Liu GJ. Cellular sources and regional variations in the expression of the neuroinflammatory marker translocator protein (TSPO) in the normal brain. Int J Mol Sci. 2018;19:2707.
Meyer JH, Cervenka S, Kim MJ, Kreisl WC, Henter ID, Innis RB. Neuroinflammation in psychiatric disorders: PET imaging and promising new targets. Lancet Psychiatry. 2020;7:1064–74.
pubmed: 33098761
pmcid: 7893630
doi: 10.1016/S2215-0366(20)30255-8
Suzuki K, Sugihara G, Ouchi Y, Nakamura K, Futatsubashi M, Takebayashi K, et al. Microglial activation in young adults with autism spectrum disorder. JAMA Psychiatry. 2013;70:49–58.
pubmed: 23404112
doi: 10.1001/jamapsychiatry.2013.272
Chauveau F, Boutin H, Van Camp N, Dolle F, Tavitian B. Nuclear imaging of neuroinflammation: a comprehensive review of [11C]PK11195 challengers. Eur J Nucl Med Mol Imaging. 2008;35:2304–19.
pubmed: 18828015
doi: 10.1007/s00259-008-0908-9
Zurcher NR, Loggia ML, Mullett JE, Tseng C, Bhanot A, Richey L, et al. [(11)C]PBR28 MR-PET imaging reveals lower regional brain expression of translocator protein (TSPO) in young adult males with autism spectrum disorder. Mol Psychiatry. 2021; 26:1659–69.
Da Silva T, Hafizi S, Watts JJ, Weickert CS, Meyer JH, Houle S, et al. In vivo imaging of translocator protein in long-term cannabis users. JAMA Psychiatry. 2019;76:1305–13.
pubmed: 31532458
pmcid: 6751758
doi: 10.1001/jamapsychiatry.2019.2516
Hafizi S, Silva TDA, Gerritsen C, Kiang M, Bagby RM, Prce I, et al. Imaging microglial activation in individuals at clinical high risk for psychosis: an in vivo PET study with [(18)F]FEPPA. Neuropsychopharmacology. 2017;42:2474–81.
pubmed: 28604733
pmcid: 5686484
doi: 10.1038/npp.2017.111
Hafizi S, Tseng HH, Rao N, Selvanathan T, Kenk M, Bazinet RP, et al. Imaging microglial activation in untreated first-episode psychosis: a PET study with [(18)F]FEPPA. Am J Psychiatry. 2017;174:118–24.
pubmed: 27609240
doi: 10.1176/appi.ajp.2016.16020171
Lai MC, Lombardo MV, Auyeung B, Chakrabarti B, Baron-Cohen S. Sex/gender differences and autism: setting the scene for future research. J Am Acad Child Adolesc Psychiatry. 2015;54:11–24.
pubmed: 25524786
pmcid: 4284309
doi: 10.1016/j.jaac.2014.10.003
Tuisku JP, Sigray P, Gaiser EC, Airas L, Al-Abdulrasul H, Brück A, et al. Effects of age, BMI and sex on the glial cell marker TSPO — a multicentre [11C]PBR28 HRRT PET study. Eur J Nucl Med Mol Imaging. 2019;46:2329–38.
pubmed: 31363804
pmcid: 6717599
doi: 10.1007/s00259-019-04403-7
Lord C, Risi S, Lambrecht L Jr, Cook EH Jr, Leventhal BL, DiLavore PC, et al. The autism diagnostic observation schedule-generic: a standard measure of social and communication deficits associated with the spectrum of autism. J Autism Dev Disord. 2000;30:205–23.
pubmed: 11055457
doi: 10.1023/A:1005592401947
Wechsler, D. Wechsler Adult Intelligence Scale—Fourth Edition. San Antonio, TX: Pearson. 2008.
Wechsler D. Wechsler Abbreviated Scale of Intelligence–Second Edition (WASI-II). San Antonio, TX. Pearson. 2011.
First MSR, Gibbon M, Williams J. Structured clinical interview for DSM-IV axis I disorders: patient edition (SCIDI/P), Version 2.0. Biometric Research. New York: New York State Psychiatric Institute; 1995.
Hormozdiari FPO, Borenstein E, Eichler EE. The discovery of integrated gene networks for autism and related disorders. Genome Res. 2015;25:142–54.
pubmed: 25378250
pmcid: 4317170
doi: 10.1101/gr.178855.114
Sheehan DV, Lecrubier Y, Sheehan KH, Amorim P, Janavs J, Weiller E, et al. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry 1998;59:22–33.
pubmed: 9881538
Woodbury-Smith MR, Robinson J, Wheelwright S, Baron-Cohen S. Screening adults for Asperger syndrome using the AQ: a preliminary study of its diagnostic validity in clinical practice. J Autism Dev Disord. 2005;35:331–35.
pubmed: 16119474
doi: 10.1007/s10803-005-3300-7
Harrison P, Oakland T. Adaptive Behavior Assessment System, Third edition (ABAS-3). San Antonio, TX: Pearson. 2015.
Lam KSL, Aman MG. The repetitive behavior scale-revised: independent validation in individuals with autism spectrum disorders. J Autism Dev Disord. 2007;37:855–66.
pubmed: 17048092
doi: 10.1007/s10803-006-0213-z
S. B. Brief Report: the Social Responsiveness Scale for Adults (SRS-A): initial results in a German cohort. J Autism Dev Disord. 2012;42:1998–9.
doi: 10.1007/s10803-011-1424-5
Roth RM, Isquith PK, Gioia GA. BRIEF—A: Behavior Rating Inventory of Executive Function— Adult Version. Psychological Assessment Resources, Lutz, FL. 2005.
August SM, Kiwanuka J, McMahon RP, Gold JM. The MATRICS Consensus Cognitive Battery (MCCB): clinical and cognitive correlates. Schizophr Res. 2012;134:76–82.
pubmed: 22093182
doi: 10.1016/j.schres.2011.10.015
Lahiri DK, Nurnberger JI Jr. A rapid non-enzymatic method for the preparation of HMW DNA from blood for RFLP studies. Nucleic Acids Res. 1991;19:5444.
pubmed: 1681511
pmcid: 328920
doi: 10.1093/nar/19.19.5444
Rathitharan G, Truong J, Tong J, Mccluskey T, Meyer JH, Mizrahi R. et al. Microglia imaging in methamphetamine use disorder: a positron emission tomography study with the 18 kDa translocator protein radioligand [F-18]FEPPA. Addict Biol.2020;26:e12876
pubmed: 32017280
pmcid: 7398821
Mizrahi R, Rusjan PM, Kennedy J, Pollock B, Mulsant B, Suridjan I, et al. Translocator protein (18 kDa) polymorphism (rs6971) explains in-vivo brain binding affinity of the PET radioligand [18F]-FEPPA. J Cereb Blood F Met. 2012;32:968–72.
doi: 10.1038/jcbfm.2012.46
Kenk M, Selvanathan T, Rao N, Suridjan I, Rusjan P, Remington G, et al. Imaging neuroinflammation in gray and white matter in schizophrenia: an in-vivo PET study with [18F]-FEPPA. Schizophr Bull. 2015;41:85–93.
pubmed: 25385788
doi: 10.1093/schbul/sbu157
Rusjan PM, Wilson AA, Mizrahi R, Boileau I, Chavez SE, Lobaugh NJ, et al. Mapping human brain fatty acid amide hydrolase activity with PET. J Cereb Blood Flow Metab. 2013;33:407–14.
pubmed: 23211960
doi: 10.1038/jcbfm.2012.180
Rusjan PM, Wilson A, Bloomfield PM, Vitcu I, Meyer JH, Houle S, et al. Quantitation of translocator protein binding in human brain with the novel radioligand [18F]-FEPPA and positron emission tomography. J Cereb Blood Flow Metab. 2011;31:1807–16.
pubmed: 21522163
pmcid: 3170950
doi: 10.1038/jcbfm.2011.55
Rusjan P, Mamo D, Ginovart N, Hussey D, Vitcu I, Yasuno F, et al. An automated method for the extraction of regional data from PET images. Psychiatry Res. 2006;147:79–89.
pubmed: 16797168
doi: 10.1016/j.pscychresns.2006.01.011
Becker EB, Stoodley CJ. Autism spectrum disorder and the cerebellum. Int Rev Neurobiol. 2013;113:1–34.
pubmed: 24290381
doi: 10.1016/B978-0-12-418700-9.00001-0
Cohen J. Statistical power analysis for the behavioral sciences. L. Hillsdale, NJ: Erlbaum Associates; 1988.
Morgan JT, Chana G, Abramson I, Semendeferi S, Courchesne E, Everall IP. Abnormal microglial-neuronal spatial organization in the dorsolateral prefrontal cortex in autism. Brain Res. 2012;1456:72–81.
pubmed: 22516109
doi: 10.1016/j.brainres.2012.03.036
Tetreault NA, Hakeem A, Jiang S, Williams BA, Allman E, Wold BJ, et al. Microglial in the cerebral cortex in autism. J Autism Dev Disord. 2012;42:2569–84.
pubmed: 22466688
doi: 10.1007/s10803-012-1513-0
Lee AS, Azmitia E, Whitaker-Azmitia PM. Developmental microglial priming in postmortem autism spectrum disorder temporal cortex. Brain Behav Immun. 2017;62:193–202.
pubmed: 28159644
doi: 10.1016/j.bbi.2017.01.019
Menassa DA, Sloan C, Chance SA. Primary olfactory cortex in autism and epilepsy: increased glial cells in autism. Brain Pathol. 2017;27:437–48.
pubmed: 27409070
doi: 10.1111/bpa.12415
Edmonson CZM, Rennert OM. Altered glial marker expression in autistic post-mortem prefrontal cortex and cerebellum. Mol Autism. 2014;5:3.
pubmed: 24410870
pmcid: 3914711
doi: 10.1186/2040-2392-5-3
Fiorentino M, Sapone A, Senger S, Camhi SS, Kadzielski SM, Buie TM, et al. Blood-brain barrier and intestinal epithelial barrier alterations in autism spectrum disorders. Mol Autism. 2016;7:49.
pubmed: 27957319
pmcid: 5129651
doi: 10.1186/s13229-016-0110-z
Ishizuka K, Fujita Y, Kawabata T, Kimura H, Iwayama Y, Inada T, et al. Rare genetic variants in CX3CR1 and their contribution to the increased risk of schizophrenia and autism spectrum disorders. Transl Psychiatry. 2017;7:e1184.
pubmed: 28763059
pmcid: 5611740
doi: 10.1038/tp.2017.173
Patel AB, Tsilioni I, Leeman SE, Theoharides TC. Neurotensin stimulates sortilin and mTOR in human microglia inhibitable by methoxyluteolin, a potential therapeutic target for autism. Proc Natl Acad Sci USA. 2016;113:E7049–E58.
pubmed: 27663735
pmcid: 5111711
doi: 10.1073/pnas.1604992113
Morgan JT, Barger N, Amaral DG, Schumann CM. Stereological study of amygdala glial populations in adolescents and adults with autism spectrum disorder. PLoS ONE. 2014;9:e110356.
pubmed: 25330013
pmcid: 4201518
doi: 10.1371/journal.pone.0110356
Adorjan I, Ahmed B, Feher V, Torso M, Krug K, Esiri M, et al. Calretinin interneuron density in the caudate nucleus is lower in autism spectrum disorder. Brain. 2017;140:2028–40.
pubmed: 29177493
pmcid: 6624365
doi: 10.1093/brain/awx131
Martin A, Boisgard R, Theze B, Van Camp N, Kuhnast B, Damont A, et al. Evaluation of the PBR/TSPO radioligand [(18)F]DPA-714 in a rat model of focal cerebral ischemia. J Cereb Blood Flow Metab. 2010;30:230–41.
pubmed: 19794397
doi: 10.1038/jcbfm.2009.205
Carson RE, Channing MA, Blasberg RG, Dunn BB, Cohen RM, Rice KC, et al. Comparison of bolus and infusion methods for receptor quantitation: application to [18F]cyclofoxy and positron emission tomography. J Cereb Blood Flow Metab. 1993;13:24–42.
pubmed: 8380178
doi: 10.1038/jcbfm.1993.6
Setiawan E, Wilson AA, Mizrahi R, Rusjan PM, Miler L, Rajkowska G, et al. Role of translocator protein density, a marker of neuroinflammation, in the brain during major depressive episodes. JAMA Psychiatry. 2015;72:268–75.
pubmed: 25629589
pmcid: 4836849
doi: 10.1001/jamapsychiatry.2014.2427
Li L, Wang W, Zhang LM, Jiang XY, Sun SZ, Sun LJ, et al. Overexpression of the 18 kDa translocator protein (TSPO) in the hippocampal dentate gyrus produced anxiolytic and antidepressant-like behavioural effects. Neuropharmacology. 2017;125:117–28.
pubmed: 28655607
doi: 10.1016/j.neuropharm.2017.06.023
Richards EM, Zanotti-Fregonara P, Fujita M, Newman L, Farmer C, Ballard ED, et al. PET radioligand binding to translocator protein (TSPO) is increased in unmedicated depressed subjects. EJNMMI Res. 2018;8:57.
pubmed: 29971587
pmcid: 6029989
doi: 10.1186/s13550-018-0401-9
Wohleb ES, Hanke M, Corona AW, Powell ND, Stiner LM, Bailey MT, et al. beta-Adrenergic receptor antagonism prevents anxiety-like behavior and microglial reactivity induced by repeated social defeat. J Neurosci. 2011;31:6277–88.
pubmed: 21525267
pmcid: 3160240
doi: 10.1523/JNEUROSCI.0450-11.2011
Sawada A, Niiyama Y, Ataka K, Nagaishi K, Yamakage M, Fujimiya M. Suppression of bone marrow-derived microglia in the amygdala improves anxiety-like behavior induced by chronic partial sciatic nerve ligation in mice. Pain. 2014;155:1762–72.
pubmed: 24907405
doi: 10.1016/j.pain.2014.05.031
Setiawan E, Attwells S, Wilson AA, Mizrahi R, Rusjan PM, Miler L, et al. Association of translocator protein total distribution volume with duration of untreated major depressive disorder: a cross-sectional study. Lancet Psychiatry. 2018;5:339–47.
pubmed: 29496589
doi: 10.1016/S2215-0366(18)30048-8
Plavén-Sigray P, Matheson GJ, Collste K, Ashok AH, Coughlin JM, Howes OD, et al. Positron emission tomography studies of the glial cell marker translocator protein in patients with psychosis: a meta-analysis using individual participant data. Biol Psychiatry. 2018;84:433–42.
pubmed: 29653835
pmcid: 7893597
doi: 10.1016/j.biopsych.2018.02.1171
Collste K, Plavén-Sigray P, Fatouros-Bergman H, Victorsson P, Schain M, Forsberg A, et al. Lower levels of the glial cell marker TSPO in drug-naive first-episode psychosis patients as measured using PET and [(11)C]PBR28. Mol Psychiatry. 2017;22:850–56.
pubmed: 28194003
doi: 10.1038/mp.2016.247
Notter T, Coughlin JM, Gschwind T, Weber-Stadlbauer U, Wang Y, Kassiou M, et al. Translational evaluation of translocator protein as a marker of neuroinflammation in schizophrenia. Mol Psychiatry. 2018;23:323–34.
pubmed: 28093569
doi: 10.1038/mp.2016.248
Daniels AM, Mandell DS. Explaining differences in age at autism spectrum disorder diagnosis: a critical review. Autism: Int J Res Pract. 2014;18:583–97.
doi: 10.1177/1362361313480277
Hallmayer J, Cleveland S, Torres A, Phillips J, Cohen B, Torigoe T, et al. Genetic heritability and shared environmental factors among twin pairs with autism. Arch Gen Psychiatry. 2011;68:1095–102.
pubmed: 21727249
pmcid: 4440679
doi: 10.1001/archgenpsychiatry.2011.76
Williams PG, Hersh JH. A male with fetal valproate syndrome and autism. Developmental Med Child Neurol. 1997;39:632–4.
doi: 10.1111/j.1469-8749.1997.tb07500.x
Williams G, King J, Cunningham M, Stephan M, Kerr B, Hersh JH. Fetal valproate syndrome and autism: additional evidence of an association. Dev Med Child Neurol. 2001;43:202–6.
pubmed: 11263692
doi: 10.1111/j.1469-8749.2001.tb00188.x
Tuisku J, Plavén-Sigray P, Gaiser EC, Airas L, Al-Abdulrasul H, Brück A, et al. Effects of age, BMI and sex on the glial cell marker TSPO - a multicentre [(11)C]PBR28 HRRT PET study. Eur J Nucl Med Mol Imaging. 2019;46:2329–38.
pubmed: 31363804
pmcid: 6717599
doi: 10.1007/s00259-019-04403-7
Danovich L, Veenman L, Leschiner S, Lahav M, Shuster V, Weizman A, et al. The influence of clozapine treatment and other antipsychotics on the 18 kDa translocator protein, formerly named the peripheral-type benzodiazepine receptor, and steroid production. Eur Neuropsychopharmacol. 2008;18:24–33.
pubmed: 17561380
doi: 10.1016/j.euroneuro.2007.04.005
Berroterán-Infante N, Balber T, Fürlinger P, Bergmann M, Lanzenberger R, Hacker M, et al. [(18)F]FEPPA: improved automated radiosynthesis, binding affinity, and preliminary in vitro evaluation in colorectal cancer. ACS Med Chem Lett. 2018;9:177–81.
pubmed: 29541356
pmcid: 5846029
doi: 10.1021/acsmedchemlett.7b00367
Cumming P. Absolute abundances and affinity states of dopamine receptors in mammalian brain: a review. Synapse. 2011;65:892–909.
pubmed: 21308799
doi: 10.1002/syn.20916
Rusjan P, Sabioni P, Di Ciano P, Mansouri E, Boileau I, Laveillé A, et al. Exploring occupancy of the histamine H3 receptor by pitolisant in humans using PET. Br J Pharmacol. 2020;177:3464–72.
pubmed: 32293706
pmcid: 7348085
doi: 10.1111/bph.15067
Hines CS, Fujita M, Zoghbi SS, Kim JS, Quezado Z, Herscovitch P, et al. Propofol decreases in vivo binding of 11C-PBR28 to translocator protein (18 kDa) in the human brain. J Nucl Med. 2013;54:64–9.
pubmed: 23148296
doi: 10.2967/jnumed.112.106872